Loading...
•
Jun 30, 2020
Checkpoint Therapeutics Q2 2020 Earnings Report
Reported financial results for the second quarter ended June 30, 2020 and recent corporate highlights.
Key Takeaways
Checkpoint Therapeutics reported their Q2 2020 financial results, highlighting the progress of cosibelimab's registration-enabling study in metastatic cutaneous squamous cell carcinoma, which is over 50% enrolled and expected to be fully enrolled by year-end.
Continued to advance the development of cosibelimab, a potential best-in-class anti-PD-L1 antibody product candidate.
The trial for cosibelimab in metastatic cutaneous squamous cell carcinoma is currently over 50% enrolled, with full enrollment anticipated around year-end.
Plan to present updated interim safety and efficacy data from the ongoing mCSCC trial at the European Society for Medical Oncology Virtual Congress 2020.
Previously reported encouraging data, including a 50% objective response rate for cosibelimab by investigator assessment in the first 14 mCSCC patients, including one complete response.
Checkpoint Therapeutics
Checkpoint Therapeutics
Forward Guidance
This press release contains forward-looking statements regarding plans to submit Biologics License Applications for cosibelimab, the potential differentiation of cosibelimab, the timing of completion of enrollment and full top-line results, and how long the company believes its cash will fund operations.